8-K: Oncolytics Biotech: REO 033 Trial Enrollment Accelerates

Oncolytics Biotech announces accelerating enrollment in its REO 033 colorectal cancer study, with a potential interim clinical update by year-end 2026.

Summary

• Oncolytics Biotech Inc. is reporting accelerated enrollment in its REO 033 clinical study for RAS-mutant, MSS metastatic colorectal cancer (mCRC).
• Most planned clinical sites for Part A of the study are now activated, and multiple patients are enrolled.
• The company anticipates having sufficient Part A data for an interim clinical update by the end of 2026, based on patient enrollment by the end of October.
• The REO 033 study is a randomized controlled trial comparing pelareorep in combination with FOLFIRI and bevacizumab against FOLFIRI and bevacizumab alone.
• Part A aims to enroll approximately 60 patients with objective response rate (ORR) as the primary endpoint.
• The U.S. Food and Drug Administration (FDA) has aligned with the company on a potential pivotal Part B expansion of REO 033, which could support accelerated approval based on ORR and full approval based on progression-free survival (PFS).
• Data from Part A will inform the design and execution of the potential Part B.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating significant progress in a key clinical trial with a clear path towards potential regulatory approval.

Positives

• Accelerating enrollment in the REO 033 study for colorectal cancer.
• Substantially all planned clinical sites for Part A are activated.
• Multiple patients are currently enrolled in the REO 033 study.
• Expectation of an interim clinical update by year-end 2026.
• Alignment with the FDA on a potential regulatory path for accelerated and full approval.
• Pelareorep has a dual mechanism of action activating innate and adaptive anti-tumor immune responses.
• Pelareorep has been administered to over 1,200 patients in clinical studies.

Negatives

• The REO 022 results, which REO 033 builds upon, were generated in a small, non-randomized study, and cross-study comparisons have inherent limitations.
• The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors, which involves complex treatment regimens.

Risks

• Regulatory outcomes for the potential Part B pivotal study.
• Challenges in trial execution and patient enrollment.
• Availability of financial resources and access to capital markets.
• Market dynamics and competitive landscape in colorectal cancer treatment.
• The inherent uncertainties in clinical trial development and the potential for results to differ materially from expectations.

Future Outlook

The company expects to have sufficient Part A data from the REO 033 study to provide an interim clinical update by year-end 2026. Data from Part A will inform the final size and execution of a potential pivotal Part B expansion, which could support accelerated approval based on objective response rate and full approval based on progression-free survival.

Management Comments

• "We are seeing strong momentum in REO 033 now that substantially all of our planned sites are open and multiple patients are on study."
• "Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end, based on the number of evaluable patients enrolled by the end of October."
• "Importantly, with site activation substantially behind us, our focus is now squarely on enrollment, execution, and generating the randomized clinical data that can inform the next stage of the program."

Industry Context

StockSavvy.ai notes that the progress in the REO 033 study aligns with the broader trend in oncology of developing targeted immunotherapies and combination treatments for difficult-to-treat cancers like RAS-mutant colorectal cancer. The FDA's alignment on a potential accelerated approval pathway highlights the unmet need and the potential for novel agents to reach patients faster.

Comparison to Industry Standards

• The REO 033 study is designed to prospectively evaluate efficacy signals observed in the earlier REO 022 study in a randomized setting.
• In REO 022, pelareorep combined with FOLFIRI and bevacizumab showed an Objective Response Rate (ORR) of 33%, compared to a historical second-line benchmark of approximately 6-11%.
• Median Progression-Free Survival (PFS) in REO 022 was 16.6 months, compared to a historical benchmark of approximately 5.7 months.
• Median Overall Survival (OS) in REO 022 was 27.0 months, compared to a historical benchmark of approximately 11.2 months.
• It is important to note that REO 022 was a small, non-randomized study, and cross-study comparisons have limitations. REO 033 aims to validate these findings in a randomized controlled trial.

Stakeholder Impact

• Shareholders: Potential positive impact from progress in clinical trials and a clearer path to regulatory approval, which could increase the value of their investment.
• Patients: Potential benefit from the advancement of a novel immunotherapy treatment for colorectal cancer.
• Healthcare Providers: Information on the progress of pelareorep may influence treatment decisions and future research.

Next Steps

• Focus on accelerating enrollment in the REO 033 study.
• Generate randomized clinical data from Part A of REO 033.
• Provide an interim clinical update by year-end 2026.
• Inform the design and execution of the potential pivotal Part B expansion based on Part A data.
• Advance pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers.

Key Dates

Recommendation

The filing shows positive clinical trial progress and FDA alignment, suggesting a promising development path for pelareorep. However, the results are still preliminary, and the company is reliant on future trial outcomes and capital markets. Therefore, a 'hold' recommendation is appropriate pending further data and de-risking events.

Keywords

colorectal cancer, pelareorep, immunotherapy, clinical trial, RAS-mutant, metastatic, Oncolytics Biotech, FDA